FY2025 EPS Estimates for BrainsWay Lowered by HC Wainwright

BrainsWay Ltd. (NASDAQ:BWAY) – HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for BrainsWay in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.18 per share for the year, down from their previous forecast of $0.32. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share.

BrainsWay Stock Performance

Shares of BWAY stock opened at $10.21 on Monday. The company’s fifty day moving average price is $10.26 and its 200-day moving average price is $9.63. The stock has a market cap of $192.22 million, a PE ratio of 102.11 and a beta of 1.29. BrainsWay has a 12 month low of $4.61 and a 12 month high of $11.79.

Institutional Investors Weigh In On BrainsWay

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP grew its stake in shares of BrainsWay by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after buying an additional 1,786 shares during the last quarter. Rhumbline Advisers grew its stake in shares of BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after acquiring an additional 2,144 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of BrainsWay by 14.6% during the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after acquiring an additional 2,446 shares in the last quarter. Lazard Asset Management LLC purchased a new position in shares of BrainsWay in the 4th quarter worth about $44,000. Finally, JPMorgan Chase & Co. boosted its stake in BrainsWay by 61.9% in the 4th quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock worth $226,000 after purchasing an additional 9,149 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.